SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAmarantus Biosciences (AMBS : OTC.BB)


From: overstock821/12/2012 1:05:16 PM
   of 9
 
Amarantus BioSciences Updates Shareholders on Execution of Expanded Corporate Strategy Amarantus BioSciences, Inc. (OTCBB: AMBS.OB - News), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today provided shareholders with an update on the execution of its expanded corporate strategy, first announced on November 1st, 2011, to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
• Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
• Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
• Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."

Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Share RecommendKeepReplyMark as Last Read


From: roger wilco4/22/2013 1:58:57 PM
   of 9
 
AMBS $.068 +.0045 Amarantus BioScience 377K volume

amarantus.com

Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.

Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.





Share RecommendKeepReplyMark as Last Read


From: roger wilco4/23/2013 3:02:41 PM
   of 9
 
AMBS .062 News out earlier today 1.7 million volume

amarantus.com

Company Overview

Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.

Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish6/14/2013 5:33:26 AM
   of 9
 
Business Summary
Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein to treat Parkinson?s diseases, as well as for other apoptosis-related disorders, including ischemic heart disease, traumatic brain injury, and orphan diseases; LymPro, blood test to diagnose Alzheimer?s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. It also owns PhenoGuard cell lines for the screening and discovery of biologic drug candidates and biomarkers of the central nervous system. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in Sunnyvale, California.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish6/14/2013 5:34:43 AM
   of 9
 
AMBS I just found out about this company. I have a vested interest in finding a cure for Alzheimers disease. My dad died from it and there is a good chance that I might do the same as well as my brothers. The first step is diagnosing it.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish6/14/2013 5:36:31 AM
   of 9
 
Business Summary
Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein to treat Parkinson?s diseases, as well as for other apoptosis-related disorders, including ischemic heart disease, traumatic brain injury, and orphan diseases; LymPro, blood test to diagnose Alzheimer?s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. It also owns PhenoGuard cell lines for the screening and discovery of biologic drug candidates and biomarkers of the central nervous system. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in Sunnyvale, California.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish6/14/2013 6:06:43 AM
   of 9
 
Company News Amarantus Engages BD Biosciences for Development of Alzheimer’s Diagnostic SUNNYVALE, Calif.-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.

“The LymPro Test is potentially the first available blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014.”

Amarantus and BD Biosciences will be focused on verifying the analytical performance characteristics of LymPro necessary to achieve reproducibility of the assay. Over time, Amarantus expects to execute multiple clinical studies and begin worldwide sales of LymPro as the first diagnostic blood test for Alzheimer’s disease.

Source - Read More: investorshangout.com

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish6/14/2013 6:16:45 AM
   of 9
 
AMBS
Management Team Gerald E. Commissiong President & CEO

Mr. Commissiong is President & CEO BioScience and a member of the Board of Directors of Amarantus, the company he co-founded with John Commissiong, PhD in 2008. From the inception of the Company, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer where his duties included strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business and corporate development. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.



John W. Commissiong, PhD Chief Scientific Officer

Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2008. Prior to Amarantus, Dr. Commissiong served as the CSO of Neurotrophics, Inc. and Prescient Neuropharma, Inc. Throughout his distinguished by Text-Enhance">career, Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.

Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the by Text-Enhance">application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.



Marc E. Faerber Chief Financial Officer

Mr. Faerber has over thirty years of experience with over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology, gastroenterology, orthopedics, diagnostics and biotechnology.

Mr. Faerber has extensive experience managing transactions including the establishment of international organizations throughout Europe and parts of Asia, international technology licensing and distribution, mergers and acquisitions, and numerous funding transactions including an initial public offering as well as other international business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management including CFO, CEO and Director. Mr. Faerber started his career at KPMG as a certified public accountant, and he has a Bachelor of Sciences by Text-Enhance">degree in Business Administration from Providence College.

Share RecommendKeepReplyMark as Last Read


From: roger wilco6/14/2013 11:55:16 AM
   of 9
 
AMBS +.0003 Getting some volume today!

Amarantus BioScience Holdings, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.


Share RecommendKeepReplyMark as Last Read